posted on 2023-08-30, 18:03authored byPhilipp Gauckler, Jae Il Shin, Federico Alberici, Vincent Audard, Annette Bruchfeld, Martin Busch, Chee Kay Cheung, Matija Crnogorac, Elisa Delbarba, Kathrin Eller, Stanislas Faguer, Kresimir Galesic, Siân Griffin, Martijn W. F. van den Hoogen, Zdenka Hrušková, Anushya Jeyabalan, Alexandre Karras, Catherine King, Harbir Singh Kohli, Gert Mayer, Rutger Maas, Masahiro Muto, Sergey Moiseev, Balazs Odler, Ruth J. Pepper, Luis F. Quintana, Jai Radhakrishnan, Raja Ramachandran, Alan D. Salama, Ulf Schönermarck, Mårten Segelmark, Lee Smith, Vladimír Tesař, Jack Wetzels, Lisa Willcocks, Martin Windpessl, Ladan Zand, Reza Zonozi, Andreas Kronbichler
Membranous nephropathy is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in a majority of patients changed the management of membranous nephropathy dramatically, and provided a rationale for B cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies including three randomized controlled trials, in which complete and partial remission of proteinuria was achieved in about two thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for membranous nephropathy, especially in patients at moderate and high risk of deterioration in kidney function. However, questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy and assessment of long-term safety and efficacy outcomes. In this review, we provide an overview of the current literature and discuss both strengths and limitations of “the new standard”.